Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Romain Guyon along with three others received the 2022 Michelson Prizes in a virtual award ceremony in collaboration with Keystone Symposia on March 24, 2023. The Michelson Prizes are awarded by Michelson Medical Research Foundation and Human Immunome Project annually to support early-career investigators working to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. These distinguished scientists comprise the 5th class of Michelson Prize laureates, joining an international group of researchers charting the future of human health.


Romain was awarded the NDM Prize Studentship at Oxford where he is currently studying for a DPhil in Clinical Medicine, based between the Jenner Institute and the Institute of Biomedical Engineering (IBME), working on the development of single-dose vaccine technologies, and microparticle drug delivery.


“Demonstration of new single-dose vaccine technology towards a first-in-man clinical application.”

Single-dose immunization could provide an effective solution to improving global vaccination coverage and easing the logistical and cost burdens during outbreaks.  Guyon uses a novel microfluidics system to generate biodegradable particles encapsulating the vaccine booster dose to be delivered with the priming vaccine dose in a single injection, delaying the booster release in the body. His successful proposal will assess the utility of this technology using the licensed rabies vaccine for single-visit post-exposure prophylaxis and assess scale-up feasibility to facilitate a first-in-human clinical trial.

Similar stories

Benemérita Universidad Autónoma de Puebla representatives visit Jenner Institute

Academic representatives from Benemérita Universidad Autónoma de Puebla (BUAP), one of the leading universities in Mexico, paid a visit to NDM’s Jenner Institute.

RECOVERY trial team wins the MRC Impact Prize

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Continued support to CPM helps it explore personalised medicine

The Dr Stanley Ho Medical Development Foundation will continue its funding support for The Centre for Personalised Medicine (CPM) for further seven years.

Shifting the needle: finding solutions for rare diseases

Rare diseases are a global health challenge. To address this, organisations around the world, including the Nuffield Department of Medicine (NDM), are working together to find solutions for patients.

Coronavirus Vaccines Research and Development Roadmap launched

The Coronavirus Vaccines Research and Development Roadmap is a comprehensive plan to galvanize a global effort to protect the world from this large and dangerous family of viruses.

Lithuanian Ambassador visits the Ludwig Institute for Cancer Research

The Lithuanian Ambassador to the United Kingdom, His Excellency Mr Eitvydas Bajarūnas, paid a visit to Professor Skirmantas Kriaučionis of the Ludwig Institute for Cancer Research at the Nuffield Department of Medicine.